Cargando…
Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1....
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225389/ https://www.ncbi.nlm.nih.gov/pubmed/34121658 http://dx.doi.org/10.7554/eLife.62927 |
_version_ | 1783712080105308160 |
---|---|
author | Ramos, M Ines Pascoal Tian, Linjie de Ruiter, Emma J Song, Chang Paucarmayta, Ana Singh, Akashdip Elshof, Eline Vijver, Saskia V Shaik, Jahangheer Bosiacki, Jason Cusumano, Zachary Jensen, Christina Willumsen, Nicholas Karsdal, Morten A Liu, Linda Langermann, Sol Willems, Stefan Flies, Dallas Meyaard, Linde |
author_facet | Ramos, M Ines Pascoal Tian, Linjie de Ruiter, Emma J Song, Chang Paucarmayta, Ana Singh, Akashdip Elshof, Eline Vijver, Saskia V Shaik, Jahangheer Bosiacki, Jason Cusumano, Zachary Jensen, Christina Willumsen, Nicholas Karsdal, Morten A Liu, Linda Langermann, Sol Willems, Stefan Flies, Dallas Meyaard, Linde |
author_sort | Ramos, M Ines Pascoal |
collection | PubMed |
description | Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 expressed on immune cells, and that LAIR-2 releases LAIR-1-mediated immune suppression. Analysis of public human datasets shows that collagens, LAIR-1 and LAIR-2 have unique and overlapping associations with survival in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 increases human T cell expansion and effector function in vivo in a mouse xenogeneic-graft versus-host disease model. In humanized mouse tumor models, NC410 reduces tumor growth that is dependent on T cells. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1(+) immune cells are localized. Our findings show that NC410 might be a novel strategy for cancer immunotherapy for immune-excluded tumors. |
format | Online Article Text |
id | pubmed-8225389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-82253892021-06-28 Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction Ramos, M Ines Pascoal Tian, Linjie de Ruiter, Emma J Song, Chang Paucarmayta, Ana Singh, Akashdip Elshof, Eline Vijver, Saskia V Shaik, Jahangheer Bosiacki, Jason Cusumano, Zachary Jensen, Christina Willumsen, Nicholas Karsdal, Morten A Liu, Linda Langermann, Sol Willems, Stefan Flies, Dallas Meyaard, Linde eLife Cancer Biology Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 expressed on immune cells, and that LAIR-2 releases LAIR-1-mediated immune suppression. Analysis of public human datasets shows that collagens, LAIR-1 and LAIR-2 have unique and overlapping associations with survival in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 increases human T cell expansion and effector function in vivo in a mouse xenogeneic-graft versus-host disease model. In humanized mouse tumor models, NC410 reduces tumor growth that is dependent on T cells. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1(+) immune cells are localized. Our findings show that NC410 might be a novel strategy for cancer immunotherapy for immune-excluded tumors. eLife Sciences Publications, Ltd 2021-06-14 /pmc/articles/PMC8225389/ /pubmed/34121658 http://dx.doi.org/10.7554/eLife.62927 Text en © 2021, Ramos et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Ramos, M Ines Pascoal Tian, Linjie de Ruiter, Emma J Song, Chang Paucarmayta, Ana Singh, Akashdip Elshof, Eline Vijver, Saskia V Shaik, Jahangheer Bosiacki, Jason Cusumano, Zachary Jensen, Christina Willumsen, Nicholas Karsdal, Morten A Liu, Linda Langermann, Sol Willems, Stefan Flies, Dallas Meyaard, Linde Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction |
title | Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction |
title_full | Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction |
title_fullStr | Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction |
title_full_unstemmed | Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction |
title_short | Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction |
title_sort | cancer immunotherapy by nc410, a lair-2 fc protein blocking human lair-collagen interaction |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225389/ https://www.ncbi.nlm.nih.gov/pubmed/34121658 http://dx.doi.org/10.7554/eLife.62927 |
work_keys_str_mv | AT ramosminespascoal cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT tianlinjie cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT deruiteremmaj cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT songchang cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT paucarmaytaana cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT singhakashdip cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT elshofeline cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT vijversaskiav cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT shaikjahangheer cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT bosiackijason cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT cusumanozachary cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT jensenchristina cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT willumsennicholas cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT karsdalmortena cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT liulinda cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT langermannsol cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT willemsstefan cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT fliesdallas cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction AT meyaardlinde cancerimmunotherapybync410alair2fcproteinblockinghumanlaircollageninteraction |